» Articles » PMID: 21214950

The Natural History of Interferon-α Induced Thyroiditis in Chronic Hepatitis C Patients: a Long Term Study

Overview
Journal Thyroid Res
Specialty Endocrinology
Date 2011 Jan 11
PMID 21214950
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Autoimmune thyroid disease is a common complication of patients with chronic hepatitis C undergoing combination pegylated interferon-α and ribavirin treatment. A small proportion develops interferon-induced thyroiditis of which the long term natural history is unknown and how it compares with de novo thyroiditis. The aim of the study is to determine the natural history of thyroid disease including antibody profile in this particular setting 36 months from the completion of therapy.

Methods: A cohort of 18 hepatitis C patients (mean age 45 ± 8 years (standard deviation)) who developed exclusively thyroiditis in this setting was followed every 12 months after the completion of therapy for 36 months. Investigations included thyrotropin, free tetra-iodothyronine, free tri-iodothyronine levels and thyroid autoantibodies.

Results: None of the patients developed any long term thyroid disease. Two patients had a prolonged hypothyroid phase of the thyroiditis early after the completion of treatment but recovered fully. The remaining 16 patients remained euthyroid. Similarly, thyroid autoantibodies all declined and returned to reference range.

Conclusions: The long term natural history in this small series of interferon induced thyroiditis was benign. If a larger series confirms a similar outcome then there is no long term residual effect on thyroid function and follow-up testing would not be warranted.

Citing Articles

A systematic review and meta-analysis of endocrine-related adverse events associated with interferon.

Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K Front Endocrinol (Lausanne). 2022; 13:949003.

PMID: 35992107 PMC: 9388759. DOI: 10.3389/fendo.2022.949003.


Autoantibodies in chronic hepatitis C: A clinical perspective.

Narciso-Schiavon J, Schiavon L World J Hepatol. 2015; 7(8):1074-85.

PMID: 26052396 PMC: 4450184. DOI: 10.4254/wjh.v7.i8.1074.


Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis.

Kesavachandran C, Haamann F, Nienhaus A PLoS One. 2013; 8(2):e55364.

PMID: 23383326 PMC: 3562313. DOI: 10.1371/journal.pone.0055364.


Thyroid dysfunction from antineoplastic agents.

Hamnvik O, Larsen P, Marqusee E J Natl Cancer Inst. 2011; 103(21):1572-87.

PMID: 22010182 PMC: 3206040. DOI: 10.1093/jnci/djr373.

References
1.
Carella C, Mazziotti G, Amato G, Braverman L, Roti E . Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004; 89(8):3656-61. DOI: 10.1210/jc.2004-0627. View

2.
Tomer Y, Blackard J, Akeno N . Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007; 36(4):1051-66. PMC: 2134787. DOI: 10.1016/j.ecl.2007.07.001. View

3.
Bindra A, Braunstein G . Thyroiditis. Am Fam Physician. 2006; 73(10):1769-76. View

4.
Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G . Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?. J Gastroenterol Hepatol. 2009; 24(6):1024-9. DOI: 10.1111/j.1440-1746.2009.05812.x. View

5.
Masood N, Ghori R, Memon A, Memon S, Memon K, Memon I . Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection. J Coll Physicians Surg Pak. 2008; 18(6):347-51. DOI: 06.2008/JCPSP.347351. View